Vol 54, No 3 (2020)
Research Paper
Published online: 2020-04-15

open access

Page views 1323
Article views/downloads 419
Get Citation

Connect on Social Media

Connect on Social Media

Fibrinogen concentrations in ischaemic stroke patients with metabolic disorders

Malgorzata Pawelczyk1, Beata Kaczorowska1, Zbigniew Baj2
Pubmed: 32293697
Neurol Neurochir Pol 2020;54(3):259-264.


Background. Hyperfibrinogenemia plays a crucial role in the coagulation cascade leading to the formation of clots. It is involved in the process of platelet aggregation, primary haemostasis, and leukocyte-endothelial cell interactions. The aim of our study was to assess the correlations between fibrinogen concentration and particular risk factors for vascular diseases and atherosclerotic changes in stroke patients. Methods. The study group consisted with 94 patients with acute ischaemic stroke with normo- or hyperglycaemia and normoor hyperlipidemia. 21 healthy subjects served as a control group. Fibrinogen level, HbA1c, and lipid profile were measured in all patients. Using a flow cytometer, we assessed CD61 positive microparticles which were defined as platelet-derived microparticles (PDMPs). The level of sP-selectin in serum was measured using the ELISA method. Results. A significant positive correlation was observed between fibrinogen concentration and sP-selectin (p = 0.001), HbA1c (p < 0.05) level, and percentage of PDMPs (p < 0.05) in the study patients. Furthermore, we noticed a significant negative correlation between fibrinogen concentration and the level of HDL (p < 0.05). No correlation was observed between fibrinogen and TC, LDL and TG levels. Conclusions and clinical implications. Our findings suggest that an elevated fibrinogen level may represent a marker of prothrombotic condition exacerbated in the state of hyperglycaemia and activation of platelets and endothelial cells. This suggests an important role played by fibrinogen in the process of thrombogenesis.

Article available in PDF format

View PDF Download PDF file


  1. Kofoed SC, Wittrup HH, Sillesen H, et al. Fibrinogen predicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques: the Copenhagen City Heart Study. Eur Heart J. 2003; 24(6): 567–576.
  2. Rudnicka AR, Mt-Isa S, Meade TW. Associations of plasma fibrinogen and factor VII clotting activity with coronary heart disease and stroke: prospective cohort study from the screening phase of the Thrombosis Prevention Trial. J Thromb Haemost. 2006; 4(11): 2405–2410.
  3. Machlus KR, Cardenas JC, Church FC, et al. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood. 2011; 117(18): 4953–4963.
  4. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost. 2003; 89(4): 601–609.
  5. Levenson J, Giral P, Razavian M, et al. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 1995; 15(9): 1263–1268.
  6. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001; 32(1): 133–138.
  7. del Zoppo GJ, Levy DE, Wasiewski WW, et al. Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke. 2009; 40(5): 1687–1691.
  8. Di Napoli M, Singh P. Is plasma fibrinogen useful in evaluating ischemic stroke patients?: why, how, and when. Stroke. 2009; 40(5): 1549–1552.
  9. Wardlaw JM, Murray V, Berge E, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2009(4): CD000213.
  10. Machlus KR, Cardenas JC, Church FC, et al. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood. 2011; 117(18): 4953–4963.
  11. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003; 170(2): 191–203.
  12. Nomura S. Function and Clinical Significance of Platelet-Derived Microparticles. Int J Hematol. 2001; 74(4): 397–404.
  13. Tousoulis D, Papageorgiou N, Androulakis E, et al. Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev. 2011; 25(6): 239–245.
  14. Herrick S, Blanc-Brude O, Gray A, et al. Fibrinogen. Int J Biochem Cell Biol. 1999; 31(7): 741–746.
  15. Schneider DJ, Taatjes DJ, Howard DB, et al. Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: a potential contributor to cardiovascular risk. J Am Coll Cardiol. 1999; 33(1): 261–266.
  16. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood. 2003; 101(7): 2661–2666.
  17. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003; 170(2): 191–203.
  18. André P, Hartwell D, Hrachovinová I, et al. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A. 2000; 97(25): 13835–13840.
  19. Yang H, Lang S, Zhai Z, et al. Fibrinogen is required for maintenance of platelet intracellular and cell-surface P-selectin expression. Blood. 2009; 114(2): 425–436.
  20. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A. 1996; 93(21): 11877–11882.
  21. Dole VS, Bergmeier W, Mitchell HA, et al. Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood. 2005; 106(7): 2334–2339.
  22. Watala C. Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus. Current Pharmaceutical Design. 2005; 11(18): 2331–2365.
  23. Nomura S, Inami N, Iwasaka T, et al. Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. Platelets. 2004; 15(3): 167–172.
  24. Nomura S, Suzuki M, Katsura K, et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis. 1995; 116(2): 235–240.
  25. Cherian P, Hankey GJ, Eikelboom JW, et al. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke. 2003; 34(9): 2132–2137.
  26. Pawelczyk M, Kaczorowska B, Baj Z, et al. The influence of hyperlipidemia on platelet activity markers in patients after ischemic stroke. Cerebrovasc Dis. 2009; 27(2): 131–137.
  27. Kuriyama N, Nagakane Y, Hosomi A, et al. Evaluation of factors associated with elevated levels of platelet-derived microparticles in the acute phase of cerebral infarction. Clin Appl Thromb Hemost. 2010; 16(1): 26–32.
  28. Pacilli A, De Cosmo S, Trischitta V, et al. Role of relationship between HbA1c, fibrinogen and HDL-cholesterol on cardiovascular disease in patients with type 2 diabetes mellitus. Atherosclerosis. 2013; 228(1): 247–248.
  29. Creager MA, Lüscher TF, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003; 108(12): 1527–1532.
  30. Lee SJ, Hong JiM, Lee SE, et al. Association of fibrinogen level with early neurological deterioration among acute ischemic stroke patients with diabetes. BMC Neurol. 2017; 17(1): 101.
  31. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007; 262(2): 157–172.
  32. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes. 1983; 32(7): 680–684.
  33. Bobbink IW, Tekelenburg WL, Sixma JJ, et al. Glycated proteins modulate tissue-plasminogen activator-catalyzed plasminogen activation. Biochem Biophys Res Commun. 1997; 240(3): 595–601.

Neurologia i Neurochirurgia Polska